CNS Pharmaceuticals, Inc. Price & Performance (CNSP)

CNS Pharmaceuticals (NASDAQ:CNSP) stock has plunged to a 52-week low of $1.49, reflecting a sharp annual decline of 99.64%. The company faces mounting financial pressure, with a negative EBITDA of $17.08 million over the past year. Despite holding more cash than debt, its rapid cash burn and trial setbacks have raised concerns.123

CNS Pharmaceuticals' clinical trial for Berubicin, targeting aggressive brain cancer, failed to show significant survival benefits compared to Lomustine. However, the drug demonstrated a favorable safety profile. The company plans to pursue further analysis and initiate trials for another drug candidate, TPI 287, later this year to bolster its pipeline.134

Short interest in CNS Pharmaceuticals has skyrocketed by 241.60% recently, signaling declining investor sentiment. Nearly 9.91% of its float is now shorted, and the company faces challenges in maintaining investor confidence. Despite this, its cash position is projected to fund operations until 2026, keeping its NASDAQ listing intact.536